At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, Eli Lilly and Company unveiled promising results from the phase 3b ADmirable trial, highlighting the efficacy of lebrikizumab (Ebglyss) in treating atopic dermatitis (AD) in patients with skin of color.
The open-label study included 90 patients aged 12 and older (weight: ≥40 kg) with moderate-to-severe AD and pigmented skin, according to the Fitzpatrick skin type scale (IV, V, or VI). Participants received a 500 mg loading dose of lebrikizumab at baseline and week 2, followed by 250 mg doses every two weeks for 16 weeks. From weeks 16 to 24, responders (defined as having an Investigator’s Global Assessment [IGA] score of 0 or 1 with a ≥2-point improvement or ≥75% improvement in the Eczema Area and Severity Index [EASI 75]) received lebrikizumab 250 mg every four weeks, while inadequate responders continued with the biweekly dosage.
At week 16,69.2%of patients achieved EASI 75,44.9%achieved EASI 90, and 44.9% had an IGA score of 0 or 1. Over 88% of patients with the darkest skin tones (Fitzpatrick V and VI) achieved EASI 75. Additionally,58.1%of patients experienced a ≥4-point improvement in their Pruritus Numeric Rating Scale (NRS), indicating significant itch relief. By week 24, these figures improved further, with 78.4% achieving EASI 75,47.3%achieving EASI 90, and 54.1% having an IGA score of 0 or 1. Moreover,61.5%of participants reported a ≥4-point improvement in itch severity.
In terms of quality of life,71.7%and 72.9% of patients experienced a ≥4-point improvement in the Dermatology Life Quality Index (DLQI) at weeks 16 and 24, respectively. Over 64% of patients with hyperpigmented lesions and 25% with hypopigmented lesions showed improvement after 24 weeks.
Regarding safety, most treatment-emergent adverse events were mild or moderate, with only one reported case each of conjunctivitis and injection site reaction. No serious adverse events occurred, and no patients discontinued treatment.
Anabela Cardoso, MD, senior vice president of immunology medical affairs at Eli Lilly and Company, emphasized that these results reinforce lebrikizumab’s value as a first-line biologic for moderate-to-severe AD, regardless of skin tone, with a favorable safety profile and the convenience of monthly maintenance dosing after the initial four-month treatment period.
Related Topics:
